Dear Investors and Supporters,
Every company has a moment where everything clicks—clinical traction, IP protection, partner outreach, and commercial readiness.
For Sen-Jam, that moment is now.
We’ve completed Phase 2 clinical data for SJP-002C and are manufacturing-ready. Global patent coverage is expanding. And our strategic licensing outreach is officially underway with Destum Partners.
This is no longer about promise—it’s about proof.
In a market where most investments feel uncertain, Sen-Jam stands apart:
- Real-world science
- Fast path to market
- Massive upside potential
- Mission-driven, ROI-focused
In 2024, our valuation rose 43%. Destum’s independent analysis points to a potential 500% valuation increase in 2025 for our 2 lead assets; SJP-002C & SJP-001—and we’re only just getting started.
With just days until our Wefunder campaign closes on April 7, this is your last chance to invest at today’s valuation before our valuation increases again.
Click here to invest or review final investor perks.
I encourage anyone with questions to set up a call with me before the campaign closes on Monday
Thank you for being part of this movement. Let’s finish strong and build the future of medicine—together.
With urgency and gratitude,
Jim